Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia.

Trial Profile

Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2012

At a glance

  • Drugs Aripiprazole; Pomaglumetad methionil
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Aug 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top